NCT05280132View on ClinicalTrials.gov

Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial

NARecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
Acute Exacerbation of COPD
Interventions
PROCEDURE

Personalized antibiotic treatment

Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.

OTHER

Usual antibiotic treatment

The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.

Trial Locations (1)

75020

RECRUITING

Intensive care department-Hospital Tenon, Paris

Sponsors

Collaborators (1)

BioMérieux
All Listed Sponsors
collaborator

BioMérieux

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER